Akums Drugs and Pharmaceuticals Ltd., India’s largest contract development and manufacturing organisation (CDMO), has reported robust consolidated results for the quarter ended 30 June 2025, with solid growth in adjusted EBITDA and adjusted PAT despite challenging market conditions.

In Q1 FY26, Akums posted total income of INR 1,051 crore and adjusted EBITDA of INR 156 crore, reflecting a 19.1% year-on-year increase. EBITDA margins improved to 14.8%, up from 12.7% last year — a 208-basis-point gain.

The flagship CDMO business contributed approximately 79% of the group’s turnover, delivering an EBITDA margin of 14.7%. The domestic branded formulation segment grew around 3% YoY, while the international branded formulation segment rose by about 2% YoY. The trade generics and API segments remained in operational loss, though management noted that these losses are narrowing.

During the quarter, Akums achieved a major milestone by securing its 1,000th Drug Controller General of India (DCGI) approval, with 27 new approvals. The company also received a patent for its extended-release combination of Doxylamine and Pyridoxine, developed using its proprietary tablet-in-tablet technology.

Pushing forward on its global ambitions, Akums obtained its first EU dossier approval for Rivaroxaban and filed its first dossier for a Dapagliflozin combination in Switzerland. Commercial supplies under the EU contract are expected to commence in April 2027. The company also received EUR 100 million as part consideration for the EU contract, boosting its cash surplus to INR 1,518 crore.

Commenting on the results, Mr Sanjeev Jain, Managing Director, said: “This date marks just over one year since we got listed. We continue to work towards strengthening the organisation with a focus on long-term growth. Our commitment to becoming a global CDMO player remains steadfast. The recent filings, along with the planned global approvals of other facilities, are setting us up for that endeavour.”

Mr Sandeep Jain, Managing Director, added: “We continue to deliver strong performance despite the industry headwinds of decreasing API prices and muted volume growth. With a sustained focus on R&D, we have been able to deliver robust growth. Achieving 1,000 DCGI approvals is a key milestone that sets Akums apart from its peers, allowing us to offer margin-accretive differentiated products. We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable and profitable growth in the years ahead.”